Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CD45RA+ T Cell Depletion in Pediatric Allogeneic PBSCT
NCT01858740Phase 2Completed
- Sponsor
- Fred Hutchinson Cancer Center
- Start
- Apr 2014
- Primary completion
- Jan 2023
- Modality
- Stem Cell Therapies
- Countries
- 1
01
Overview
A Phase 2 trial of Allogeneic CD34+-enriched and CD45RA-depleted PBSCs in acute lymphoblastic leukemia (ALL), acute myeloid leukemia (AML), Chronic Myeloid Leukemia (CML), myelodysplastic syndrome (MDS), sponsored by Fred Hutchinson Cancer Center. Started Apr 2014; status: completed.
02
Drugs
Allogeneic CD34+-enriched and CD45RA-depleted PBSCs
03
Conditions
acute lymphoblastic leukemia (ALL)acute myeloid leukemia (AML)Chronic Myeloid Leukemia (CML)myelodysplastic syndrome (MDS)
Beyond the preview
Go deeper on NCT01858740.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01858740.